Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging

The Journal of Nuclear Medicine

article

Christian Schmidkonz¹  Torsten Kuwert¹  Armin Atzinger¹  Michael Cordes¹  Georg Schett³  Andreas Ramming³  Theresa Götz² 

[1] Department of Nuclear Medicine, Friedrich–Alexander University Erlangen–Nürnberg and University Hospital Erlangen;Institute for Medical Engineering, Technical University of Applied Sciences Amberg–Weiden;Rheumatology and Immunology, Department of Internal Medicine 3, Friedrich–Alexander University Erlangen–Nürnberg and University Hospital Erlangen

关键词: fibroblast activation protein;    inflammatory diseases;    PET;    molecular imaging;    fibrosis;   

DOI  :  10.2967/jnumed.122.264205

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Fibroblast activation protein-α (FAP-α) is a type II transmembrane glycoprotein that is overexpressed in activated fibroblasts such as those in the stroma of tumors or in the fibrotic processes accompanying various benign diseases. The recent development and clinical implementation of radiolabeled quinolone-based tracers suitable for PET that act as FAP inhibitors (FAPIs) have opened a new perspective in molecular imaging. Although multiple studies have investigated the use of FAPI imaging in cancer, evidence concerning its use in nonmalignant diseases is still scarce. Herein, we provide a comprehensive review of FAPI imaging in nonmalignant diseases to clarify the current and potential role of this class of molecules in nuclear medicine.

【 授权许可】

CC BY